Experts Call for Ecosystem-Wide Approach to Address Disparities in Stem Cell Therapy Access
Leading experts at the 2025 Transplant and Cellular Therapy Meetings emphasize the critical need to address social vulnerabilities affecting patient access to stem cell transplants and CAR T-cell therapies.
ACCESS Trial Shows Promising Survival Rates with PTCy GVHD Prophylaxis in HLA-Mismatched Transplants
Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants.
Dana-Farber Researchers to Present Groundbreaking Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber researchers will showcase novel findings on multiple myeloma treatment outcomes based on Duffy genotype at the 2025 Tandem Meetings, revealing significant implications for personalized therapy selection.
Narsoplimab Shows Promising Real-World Outcomes in TA-TMA Patients at 2025 Tandem Meetings
Omeros Corporation will present real-world data from 128 transplant patients treated with narsoplimab for TA-TMA under an expanded access program at the 2025 Tandem Meetings in Honolulu.
Social Determinants Drive Disparities in Pediatric Stem Cell Transplant Outcomes and Access
Children from high-poverty neighborhoods face 25% transplant-related mortality compared to 20% in low-poverty areas, with Black children experiencing 65% higher risk of transplant-related mortality.